Mayaro virus, an alphavirus forgotten in Colombia: possible cause of affectation of public health

Virus Mayaro, un alphavirus olvidado en Colombia: posible efecto sobre la salud pública Mayaro virus, an alphavirus forgotten in Colombia: possible effect on public health

Published 2021-04-14


https://doi.org/10.30554/archmed.21.2.3493.2021
Open | Download
PDF (Spanish) FLIP HTML (Spanish) epub (Spanish) XML (Spanish)
Issue
Vol. 21 No. 2 (2021): .
Section
Artículos de Revisión
How to Cite
Lozada Martínez, I., Bolaño Romero, M. ., & Arroyo Salgado, B. . (2021). Mayaro virus, an alphavirus forgotten in Colombia: possible cause of affectation of public health: Mayaro virus, an alphavirus forgotten in Colombia: possible effect on public health. Archivos De Medicina , 21(2). https://doi.org/10.30554/archmed.21.2.3493.2021
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
DOI

https://doi.org/10.30554/archmed.21.2.3493.2021
Dimensions
PlumX

How to Cite

Lozada Martínez, I., Bolaño Romero, M. ., & Arroyo Salgado, B. . (2021). Mayaro virus, an alphavirus forgotten in Colombia: possible cause of affectation of public health: Mayaro virus, an alphavirus forgotten in Colombia: possible effect on public health. Archivos De Medicina , 21(2). https://doi.org/10.30554/archmed.21.2.3493.2021

Download Citation

license
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ivan Lozada Martínez
Universidad de Cartagena
https://orcid.org/0000-0002-1960-7334 ORCID
Maria Bolaño Romero
Universidad de Cartagena
https://orcid.org/0000-0001-8962-6947 ORCID
Bárbara Arroyo Salgado
Universidad de Cartagena
https://orcid.org/0000-0002-8466-348X ORCID
Show authors biography

Ivan Lozada Martínez,

Estudiante de Medicina, Grupo de Investigación Ciencias Biomédicas, Toxicológicas y Ambientales (BIOTOXAM), Facultad de Medicina, Universidad de Cartagena, Cartagena, Colombia.

Maria Bolaño Romero,

Estudiante de Medicina, Grupo de Investigación Ciencias Biomédicas, Toxicológicas y Ambientales (BIOTOXAM), Facultad de Medicina, Universidad de Cartagena

Bárbara Arroyo Salgado,

Doctora en Ciencias Biomédicas, Líder Grupo de Investigación Ciencias Biomédicas, Toxicológicas y Ambientales (BIOTOXAM), Facultad de Medicina, Universidad de Cartagena

About Mayaro virus, there is currently little knowledge of its transmission and pathogenesis. It is known to inhabit different areas of the Western Hemisphere and is distributed in Central and South America and is transmitted by the Aedes aegypti and albopictus (Diptera: Culicidae). Numerous authors have focused their research given coexistence in scenarios where the circulations of all these viruses can somehow overlap and generate mixed infections. This agent has been gaining prominence at the public health level, due to the possibility of causing high risk of outbreaks with serious clinical manifestations similar to that of Zika viruses, Chikungunya virus and Dengue, in several countries, such as Trinidad, Brazil, Mexico, Venezuela, Honduras, Salvador, Costa Rica, Panama, Peru, Argentina, Suriname, Guyana, Venezuela, Ecuador and Bolivia. Colombia is looking forward to a concomitant onset in the near future along with ZIKV and CHIKV. Taking into account the above, a thorough search was carried out of the existing literature, on Mayaro virus, its molecular structure, transmission cycle, clinical symptomatology, diagnostic methods, risk factors, control and prevention, as well as treatment, to learn a broader picture of the problem that lurks. All this, through search engines like PubMed, Science Direct, Clinical Key and Ebsco.

Article visits 674 | PDF visits 495

Downloads

Download data is not yet available.
  1. Acosta-Ampudia Y, Monsalve DM, Rodríguez Y, Pacheco Y, Anaya JM, Ramírez-Santana C. Mayaro: an emerging
  2. viral threat? Emerg Microbes Infect. 2018; 7(1):1-11. DOI: 10.1038/s41426-018-0163-5
  3. Cardona-Ospina JA, Villamil-Gómez WE, Jimenez-Canizales CE, Castañeda-Hernandez DM, Rodríguez-Morales
  4. AJ. Estimating the burden of disease and the economic cost attributable to chikungunya, Colombia, 2014.
  5. Trans R Soc Trop Med Hyg. 2015; 109(12):793-802. DOI: 10.1093/trstmh/trv094
  6. Pacheco O, Beltrán M, Nelson CA, Valencia D, Tolosa N, Farr SL, et al. Zika Virus Disease in Colombia - Preliminary
  7. Report. N Engl J Med. 2020; 383(6):1-10. DOI: 10.1056/NEJMoa1604037
  8. Llagonne-Barets M, Icard V, Leparct-Goffart I, Prat C, Perpoint T, André P, et al. A case of Mayaro virus infection
  9. imported from French Guiana. J Clin Virol. 2016;77:66–68. DOI: 10.1016/j.jcv.2016.02.013
  10. Receveur MC, Grandadam M, Pistone T, Malvy D. Infection with Mayaro virus in a French traveller returning
  11. from the Amazon region, Brazil, January, 2010. Euro Surveill. 2010; 15(18):1-4. DOI: 10.3201/eid1804.111717
  12. Theilacker C, Held J, Allering L, Emmerich P, Schmidt-Chanasit J, Kern WV, et al. Prolonged polyarthralgia
  13. in a German traveller with Mayaro virus infection without inflammatory correlates. BMC Infect Dis. 2013;
  14. :1-4. DOI: 10.1186/1471-2334-13-369
  15. Instituto Nacional de Salud. Comportamiento de las arbovirosis a periodo epidemiológico IX de 2018. Colombia:
  16. Disponible en:
  17. https://www.ins.gov.co/buscador-eventos/BoletinEpidemiologico/2018%20Bolet%C3%ADn%20epidemiol%C3%B3gico%20semana%2039.pdf
  18. Arredondo AE, Guerrero G, de Quezada F, Santana O. Presencia y diseminación del Dengue, Chikungunya
  19. y otras arbovirosis en las Américas. Rev Med Electrón. 2019; 41(2):423-434. ID: biblio-1004278
  20. Archivos de Medicina Volumen 21 Nº 2 - Julio-Diciembre de 2021
  21. Universidad de Manizales - Facultad de Ciencias de la Salud
  22. Rodríguez AJ, Anaya JM. Impact of emerging arthritogenic arboviruses in Colombia and Latin America.
  23. Rev Colomb Reumatol. 2016; 23(3):145-147. DOI: 10.1016/j.rcreu.2016.08.001
  24. Esposito DL, Lopes- da Fonseca BA. Will Mayaro virus be responsible for the next outbreak of an arthropodborne
  25. virus in Brazil? Braz J Infect Dis. 2017; 21(5):540-544. DOI: 10.1016/j.bjid.2017.06.002
  26. Lednicky J, Beau VM, Elbadry M, Loeb J, Telisma T, Chavannes S, et al. Mayaro Virus in Child with Acute
  27. Febrile Illness, Haiti, 2015. Emerg Infect Dis. 2016; 22(11):2000-2002. DOI: 10.3201/eid2211.161015
  28. Anderson CR, Downs WG, Wattley GH, Ahin NW, Reese AA. Mayaro virus: a new human disease agent. Am
  29. J Trop Med Hyg. 1957; 6(6):1012-1016. DOI: 10.4269/ajtmh.1957.6.1012
  30. Auguste AJ, Liria J, Forrester NL, Giambalvo D, Moncada M, Long KC, et al. Evolutionary and Ecological
  31. Characterization of Mayaro Virus Strains Isolated during an Outbreak, Venezuela, 2010. Emerg Infect Dis.
  32. ; 21(10):1742-1750. DOI: 10.3201/eid2110.141660
  33. Lavergne A, de Thoisy B, Lacoste V, Pascalis H, Pouliquen JF, Mercier V, et al. Mayaro virus: complete nucleotide
  34. sequence and phylogenetic relationships with other alphaviruses.Virus Res. 2006 May; 117(2):283-90.
  35. DOI: 10.1016/j.virusres.2005.11.006
  36. Mavian C, Rife BD, Dollar JJ, Cella E, Ciccozzi M, Prosperi MC, et al. Emergence of recombinant Mayaro virus
  37. strains from the Amazon basin. Sci Rep. 2017; 7(1):1-11. DOI: 10.1038/s41598-017-07152-5
  38. Wiggins K, Eastmond B, Alto BW. Transmission potential of Mayaro virus in Florida Aedes aegypti and Aedes
  39. albopictus mosquitoes. Med Vet Entomol. 2018; 32(4):436-442. DOI: 10.1111/mve.12322
  40. Muñoz M, Navarro JC. Mayaro: un arbovirus re-emergente en Venezuela y Latinoamerica. Biomédica. 2012;
  41. (2):286-302. DOI: 10.7705/biomedica.v32i2.647
  42. Rey J, Lounibos P. Ecología de Aedes aegypti y Aedes albopictus. Biomédica. 2015;35:177-85.
  43. DOI: 10.7705/biomedica.v35i2.2514
  44. Ganjian N, Riviere-Cinnamond A. Mayaro virus in Latin America and the Caribbean. Rev Panam Salud Publica.
  45. ; 44:1-11. DOI: 10.26633/RPSP.2020.14
  46. Blohm G, Elbadry MA, Mavian C, Stephenson C, Loeb J, White S, et al. Mayaro as a Caribbean traveler: Evidence
  47. for multiple introductions and transmission of the virus into Haiti. Int J Infect Dis. 2019; 87:151-153.
  48. DOI: 10.1016/j.ijid.2019.07.031
  49. Diagne CT, Bengue M, Choumet V, Hamel R, Pompon J, Missé D. Mayaro Virus Pathogenesis and Transmission
  50. Mechanisms. Pathogens. 2020; 9(9):1-23. DOI: 10.3390/pathogens9090738
  51. Bogoch I, Brady OJ, Kraemer M, German M, Creatore M, Brent S, et al. Potential for Zika virus introduction and
  52. transmission in resource-limited countries in Africa and the Asia-Pacific region: A modelling study. Lancet
  53. Infect. Dis. 2016; 16:1237-1245. DOI:10.1016/S1473-3099(16)30270-5
  54. Sun J, Wu D. Mayaro virus, a regional or global threat? Travel Med Infect Dis. 2019; 32:1-1.
  55. DOI: 10.1016/j.tmaid.2019.07.018
  56. Mackay IM, Arden KE. Mayaro virus: a forest virus primed for a trip to the city. Microbes Infect. 2016;
  57. (12):724-734. DOI: 10.1016/j.micinf.2016.10.007
  58. Napoleão-Pego P, Pinto-Gomes L, Provance DW, De-Simone SG. Mayaro virus disease. J Hum Virol Retrovirol.
  59. ; 1(3):1-11. DOI: 10.15406/jhvrv.2014.01.00018
  60. Junt T, Heraud J, Lelarge J, Labeau B, Talarmin A. Determination of natural versus laboratory human infection.
  61. Epidemiol Infect. 1999;123:511-13. DOI:10.1017/s0950268899003180
  62. Santiago FW, Halsey ES, Siles C, Vilcarromero S, Guevara C, Silvas JA, et al. Long-Term arthralgia after Mayaro
  63. virus infection correlates with sustained pro-inflammatory cytokine response. PLoS Negl Trop Dis.
  64. ; 9(10):1-14. DOI:10.1371/journal.pntd.0004104
  65. Paniz AE, Rodriguez AJ, Blohm G, Marquez M, Villamil WE. ChikDenMaZika Syndrome: the challenge of
  66. diagnosing arboviral infections in the midst of concurrent epidemics. Ann Clin Microbiol Antimicrob. 2016;
  67. (1):42. DOI: 10.1186/s12941-016-0157-x
  68. Wang E, Paessler S, Aguilar PV, Carrara AS, Ni H, Greene IP, et al. Reverse transcription-PCR-enzyme-linked
  69. immunosorbent assay for rapid detection and differentiation of alphavirus infections. J Clin Microbiol. 2006;
  70. (11):4000-4008. DOI: 10.1128/JCM.00175-06
  71. Halsey ES, Siles C, Guevara C, Vilcarromero S, Jhonston EJ, Ramal C, et al. Mayaro virus infection, Amazon
  72. Basin region, Peru, 2010–2013. Emerg Infect Dis. 2013; 19(11):1839–1842. DOI: 10.3201/eid1911.130777
  73. Revisión de Tema
  74. Virus Mayaro, un Alphavirus Olvidado pp 523-531
  75. Bronzoni RV, Moreli ML, Cruz AC, Figueiredo LT. Multiplex nested PCR for Brazilian Alphavirus diagnosis.
  76. Trans R Soc Trop Med Hyg. 2004; 98(8):456-461. DOI: 10.1016/j.trstmh.2003.09.002
  77. Naveca FG, Nascimento VAD, Souza VC, Nunes BTD, Rodrigues DSG, Vasconcelos PF. Multiplexed reverse
  78. transcription real-time polymerase chain reaction for simultaneous detection of Mayaro, Oropouche, and
  79. Oropouche-like viruses. Mem Inst Oswaldo Cruz. 2017; 112(7):510-513. DOI: 10.1590/0074-02760160062
  80. Waggoner JJ, Rojas A, Mohamed-Hadley A, Arévalo-de Guillén Y, Pinsky BA. Real-time RT-PCR for Mayaro
  81. virus detection in plasma and urine. J Clin Virol. 2018; 98:1-4. DOI: 10.1016/j.jcv.2017.11.006
  82. Powers A, Aguilar P, Chandler L, Brault A, Meakins T, Watts D, et al. Genetic relationships among Mayaro and
  83. Una viruses suggest distinct patterns of transmission. Am J Trop Med Hyg. 2006;75:461-9.
  84. DOI: 10.4269/ajtmh.2006.75.461
  85. Aguilar MA, Del Valle J, Silva W, Gil T, Levy S, Bazán J, et al. An emerging public health threat: Mayaro
  86. virus increases its distribution in Peru. Int J Infect Dis. 2020; 92:253-258.
  87. DOI: 10.1016/j.ijid.2020.01.024
  88. Sakkas H BP, Franks A, Papadopoulou C. Oropouche fever: A review. Viruses. 2018; 10(4):1-16.
  89. Weise WJ, Hermance ME, Forrester N, Adams AP, Langsjoen R, Gorchakov R, et al. A novel live-attenuated
  90. vaccine candidate for mayaro fever. PLoS Negl Trop Dis. 2014; 8(8):1-9. DOI: 10.1371/journal.pntd.0002969
  91. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X. Chikungunya in the Americas. Lancet.
  92. ; 383(9916):514-514. DOI: 10.1016/S0140-6736(14)60185-9
  93. Choi H, Kudchodkar SB, Reuschel EL, Asija K, Borole P, Ho M, et al. Protective immunity by an engineered
  94. DNA vaccine for Mayaro virus. PLoS Negl Trop Dis. 2019; 13(2):1-21. DOI: 10.1371/journal.pntd.0007042
  95. Hoque H, Islam R, Ghosh S, Rahaman MM, Jewel NA, Miah MA. Implementation of in silico methods to predict
  96. common epitopes for vaccine development against Chikungunya and Mayaro viruses. Heliyon. 2021;
  97. (3):1-11. DOI: 10.1016/j.heliyon.2021.e06396
  98. Amorim R, de Meneses MDF, Borges JC, da Silva Pinheiro LC, Caldas LA, Aires L, et al. Thieno[2,3-b]pyridine
  99. derivatives: a new class of antiviral drugs against Mayaro virus. Arch Virol. 2017; 162(6):1577-1587.
  100. DOI: 10.1007/s00705-017-3261-0
  101. Ferreira PG, Ferraz AC, Figueiredo JE, Lima CF, Rodrigues VG, Taranto AG, et al. Detection of the antiviral
  102. activity of epicatechin isolated from Salacia crassifolia (Celastraceae) against Mayaro virus based on
  103. protein C homology modelling and virtual screening. Arch Virol. 2018; 163(6):1567-1576.
  104. DOI: 10.1007/s00705-018-3774-1
  105. Valencia-Marín BS, Duarte-Gandica I, Aguirre-Obando OA. The Mayaro virus and its potential epidemiological
  106. consequences in Colombia: an exploratory biomathematics analysis. Parasit Vectors. 2020; 13(1):1-16.
  107. DOI: 10.1186/s13071-020-04354-1

Information

Keywords

QR code

Sistema OJS 3.4.0.10 - Metabiblioteca |